Showing 2871-2880 of 3039 results for "".
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- Ocutech Adds 3x and 5.5x Power Options for the Falcon Autofocus Bioptichttps://modernod.com/news/ocutech-adds-3x-and-5-5x-power-options-for-the-falcon-autofocus-bioptic/2476672/The Ocutech Falcon Autofocus Bioptic self-focusing low vision telescope is now available in 3x, 4x and 5.5x powers. Released in late 2018 in its original 4x power, the Falcon Autofocus bioptic is now being prescribed in the US and in 11 foreign countries. The Falcon’s Time-of-Flight (ToF)
- Glaucoma Drugs Continue to Battle for Market Sharehttps://modernod.com/news/glaucoma-drugs-continue-to-battle-for-market-share/2476655/Two new glaucoma drugs introduced in the US in 2018 continue to battle for market share. Rhopressa, from Aerie Pharmaceuticals, got out of the gate faster than Vyzulta from Bausch Health. The growth rate for both drugs slowed in the first quarter of 2019, which is normal after a product launch, a
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- Roche’s Purchase of Spark Therapeutics Faces Further Delay Amid Scrutiny From US, UK Regulatorshttps://modernod.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/The US Federal Trade Commission requested additional information and documentary material from Roche and Spark Therapeutics in connection with its review of the companies’ pending deal, the drugmakers reported Monday. Roche noted that as a result, its $4.3-billion offer to acquire Spark has
- Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Millionhttps://modernod.com/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million/2476641/Biogen announced that it has completed its acquisition of gene therapy company Nightstar Therapeutics, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical ass
- SightLife Announces 100,000 Corneal Transplants in India Since Program Inception in 2009https://modernod.com/news/sightlife-announces-100000-corneal-transplants-in-india-since-program-inception-in-2009/2476639/SightLife announced that, together with its partners in India, 100,000 individuals suffering from corneal blindness have had their sight restored through a corneal transplant in the last 10 years since operations began in India. SightLife is a nonprofit global health organization dedicated to eli
- Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugshttps://modernod.com/news/verseon-showcases-oral-candidates-for-next-generation-diabetic-eye-disease-drugs/2476626/Verseon presented a new class of oral candidate drugs which could change the treatment and prevention of diabetic macular edema (DME). “Our oral development candidate, a novel inhibitor of plasma kallikrein, has the potential to redefine how DME is treated,” Dr. Anirban Datta, Verse
- Evaluation of a Remote Diagnosis Imaging Model vs Dilated Eye Examination in Referable Macular Degenerationhttps://modernod.com/news/evaluation-of-a-remote-diagnosis-imaging-model-vs-dilated-eye-examination-in-referable-macular-degeneration/2476596/Researchers examined if the identification of referable macular degeneration could be done using the remote diagnosis imaging model as a clinical screening tool. They conducted a nonrandomized study of 159 patients in facilities with high rates of diabetic retinopathy and age-related macular dege
- Preclinical Studies Demonstrate Galimedix’s GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Modelshttps://modernod.com/news/preclinical-studies-demonstrate-galimedixs-gal-101-shows-neuroprotective-effect-from-toxic-amyloid-beta-in-dry-amd-and-glaucoma-models/2476564/Galimedix Therapeutics presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. Further, investiga